Stockscreener 앱 받기
114.33
0.16%
-0.18
시간 외 거래:
114.30
-0.03
-0.03%
Arcellx Inc 주식(ACLX)의 최신 뉴스
Arcellx (ACLX) CFO gifts 5,000 shares to family foundation - Stock Titan
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders? (2026-03-19) - Seeking Alpha
JPMorgan Chase & Co. Decreases Holdings in Arcellx, Inc. $ACLX - MarketBeat
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
Gilead buys Arcellx to fast-track next-gen myeloma drug - MSN
Arcellx, Inc.Common Stock (NQ: ACLX - The Chronicle-Journal
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - AOL.com
Institution Moves: Is Arcellx Inc stock a smart retirement pickWeekly Trade Analysis & Risk Managed Investment Signals - baoquankhu1.vn
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth - MarketBeat
Arcellx and Aardvark Therapeutics Compared - National Today
(ACLX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders? (2026-03-16) - Seeking Alpha
Arcellx, Inc. $ACLX Position Lifted by HighVista Strategies LLC - MarketBeat
Bamco Inc. NY Increases Stake in Arcellx, Inc. - National Today
Bamco Inc. NY Has $45.17 Million Stake in Arcellx, Inc. $ACLX - MarketBeat
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Arcellx set to report earnings amid $7.8B Gilead deal By Investing.com - Investing.com Nigeria
Integral Health Asset Management LLC Invests $12.32 Million in Arcellx, Inc. $ACLX - MarketBeat
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc.ACLX - FinancialContent
Gilead Sciences to buy Arcellx in deal worth up to $7.8B - MSN
Shareholder Alert: The Ademi Firm Investigates Whether Arcellx Inc. Is Obtaining a Fair Price for Its Public Shareholders - 富途牛牛
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? - sharewise.com
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Declines By 38.0% - MarketBeat
Arcellx shares surge after Gilead announces $7.8B takeover deal - MSN
Victory Capital Management Inc. Has $14.13 Million Stock Position in Arcellx, Inc. $ACLX - MarketBeat
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification - simplywall.st
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Insider Monkey
Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders? - Sahm
Arcellx set to report earnings amid $7.8B Gilead deal - Investing.com
American Century Companies Inc. Has $33.82 Million Position in Arcellx, Inc. $ACLX - MarketBeat
Gilead to buy US biotech Arcellx for up to $7.8 billion - MSN
Blue Owl Capital Holdings LP Buys Shares of 26,823 Arcellx, Inc. $ACLX - MarketBeat
Arcellx (NASDAQ: ACLX) backs $115 cash plus $5 CVR tied to $6B anito-cel sales - Stock Titan
(ACLX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcellx Inc share price - Capital.com
Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036? - Traders Union
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga
Multiple Myeloma Market 2026: Gilead Sciences Acquires Arcellx for $7.8B to Control CAR-T Therapy - openPR.com
Arcellx (ACLX) director gifts 101,164 shares to family foundation - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Alkermes (ALKS) and Progyny (PGNY) - The Globe and Mail
Arcellx Inc stock hits all-time high at 114.27 USD - Investing.com Australia
Are ACLX, VRE, LSF Obtaining Fair Deals for their Shareholders? - Stock Titan
Gilead Sciences’ Yeztugo Revenue Is Set to Jump 400%: Here’s What Comes Next - TIKR.com
Arcellx (NASDAQ:ACLX) Hits New 52-Week HighStill a Buy? - MarketBeat
Arcellx Inc stock hits all-time high at 114.27 USD By Investing.com - Investing.com UK
Arcellx, Inc. (ACLX) Stock Analysis: Navigating Biotech’s Cutting Edge with Strategic Alliances - DirectorsTalk Interviews
Cowen Downgrades Arcellx, Inc. (ACLX) to Hold on March 2, 2026 - Meyka
ACLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance - Yahoo Finance
Arcellx stock rating cut to Hold by TD Cowen on Gilead deal - Investing.com India
Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement - The Globe and Mail
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement - The Globe and Mail
TD Cowen Downgrades Arcellx to Hold From Buy - marketscreener.com
1.20%
0.06%
자본화:
|
볼륨(24시간):